[(2R,3S,4R,5R)-4-cyano-5-(2,4-dioxopyrimidin-1-yl)-4-methyl-2-[[[[(2S)-1-oxo-1-propan-2-yloxypropan-2-yl]amino]-phenoxyphosphoryl]oxymethyl]oxolan-3-yl] 2-methylpropanoate | 1605283-94-0

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘧啶核苷
• 英文名称: [(2R,3S,4R,5R)-4-cyano-5-(2,4-dioxopyrimidin-1-yl)-4-methyl-2-[[[[(2S)-1-oxo-1-propan-2-yloxypropan-2-yl]amino]-phenoxyphosphoryl]oxymethyl]oxolan-3-yl] 2-methylpropanoate
• CAS: 1605283-94-0
• 化学式: C₂₇H₃₅N₄O₁₀P
• 分子量: 606.569
• InChiKey: UBNDMWKXZWYWLT-SLEMNBQQSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  42
• 可旋转键数：
  14
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.52
• 拓扑面积：
  183
• 氢给体数：
  2
• 氢受体数：
  12

反应信息

• 作为产物：
  描述：

  索非布韦中间体 在 4-二甲氨基吡啶 、 2,2,6,6-tetramethylpiperidinylmagnesium chloride lithium chloride complex 、 三乙胺 作用下， 以 四氢呋喃 、 N-甲基吡咯烷酮 、 水 为溶剂， 反应 6.83h， 生成 [(2R,3S,4R,5R)-4-cyano-5-(2,4-dioxopyrimidin-1-yl)-4-methyl-2-[[[[(2S)-1-oxo-1-propan-2-yloxypropan-2-yl]amino]-phenoxyphosphoryl]oxymethyl]oxolan-3-yl] 2-methylpropanoate
  参考文献：
  名称：

  [EN] 2'-METHYL SUBSTITUTED NUCLEOSIDE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES
  [FR] DÉRIVÉS DE NUCLÉOSIDES 2'-MÉTHYLE SUBSTITUÉS ET LEURS PROCÉDÉS D'UTILISATION DANS LE TRAITEMENT DE MALADIES VIRALES

  摘要：

  本发明涉及式(I)的2'-甲基取代核苷衍生物及其药学上可接受的盐，其中R、R1、R2和R3如本文所定义。本发明还涉及包含至少一种2'-甲基取代核苷衍生物的组合物，以及使用这些2'-甲基取代核苷衍生物治疗或预防患者HCV感染的方法。

  公开号：

  WO2014062596A1

文献信息

• 2'-METHYL SUBSTITUTED NUCLEOSIDE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES
  申请人：Girijavallabhan Vinay

  公开号：US20140128339A1

  公开（公告）日：2014-05-08

  The present invention relates to 2′-Methyl Substituted Nucleoside Derivatives of Formula (I): and pharmaceutically acceptable salts thereof, wherein R, R 1 , R 2 and R 3 , are as defined herein. The present invention also relates to compositions comprising at least one 2′-Methyl Substituted Nucleoside Derivative, and methods of using the 2′-Methyl Substituted Nucleoside Derivatives for treating or preventing HCV infection in a patient.
• NOVEL DISINTEGRATION SYSTEMS FOR PHARMACEUTICAL DOSAGE FORMS
  申请人：Merck Sharp & Dohme Corp.

  公开号：US20160346198A1

  公开（公告）日：2016-12-01

  The present disclosure is directed to disintegration systems for solid pharmaceutical dosage forms, which allow rapid disintegration of solid dosage forms that comprise solid dispersion formulations that include pharmaceutically active agents, polymers and optionally surfactants. The present disclosure is also directed to solid pharmaceutical dosage forms, such as tablets, comprising solid dispersion formulations and the disintegration systems, to methods for preparing the disintegration systems, and to methods for preparing the solid pharmaceutical dosage forms.
• [EN] 2'-METHYL SUBSTITUTED NUCLEOSIDE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES<br/>[FR] DÉRIVÉS DE NUCLÉOSIDES 2'-MÉTHYLE SUBSTITUÉS ET LEURS PROCÉDÉS D'UTILISATION DANS LE TRAITEMENT DE MALADIES VIRALES
  申请人：MERCK SHARP & DOHME

  公开号：WO2014062596A1

  公开（公告）日：2014-04-24

  The present invention relates to 2'-Methyl Substituted Nucleoside Derivatives of Formula (I): and pharmaceutically acceptable salts thereof, wherein R, R1, R2 and R3, are as defined herein. The present invention also relates to compositions comprising at least one 2'-Methyl Substituted Nucleoside Derivative, and methods of using the 2'-Methyl Substituted Nucleoside Derivatives for treating or preventing HCV infection in a patient.

  本发明涉及式(I)的2'-甲基取代核苷衍生物及其药学上可接受的盐，其中R、R1、R2和R3如本文所定义。本发明还涉及包含至少一种2'-甲基取代核苷衍生物的组合物，以及使用这些2'-甲基取代核苷衍生物治疗或预防患者HCV感染的方法。